Cellular 'glue' resists breast cancer

April 20, 2012

Early detection and advances in the treatment for breast cancer have improved the chances of survival, however new avenues for treatment are still needed in the battle against this disease. New research published in BioMed Central's open access journal Breast Cancer Research demonstrates that the protein Perp, associated with desmosomes (the glue that sticks cells together), is involved in suppressing breast cancer and provides a potential new target for future treatment.

Desmosomes attach neighbouring cells together and it is these tiny collections of proteins which are responsible for the mechanical strength of organs and tissues within the body. Desmosomes are also thought to be involved in helping to suppress cancer. Researchers from Stanford University, UC Berkeley, and UC Davis have discovered that the protein Perp is found associated with desmosomes in breast epithelial cells.

Dr Laura Attardi, who led the research, described how loss of Perp affected normal breast tissue function in mice. She said, "Perp deficiency caused defects in desmosomal in breast epithelial cells. At the same time there was an enhanced inflammatory response in the breast tissue, and tumours tended to develop more quickly. We also found in the lab that had abnormally low levels of Perp."

These results show that Perp is part of the cellular glue that fastens cells together and has a dual role in the prevention of breast cancer. promote cancer and lack of cell adhesion is part of the progression of cancer to metastasis. Perp may well be a new indicator for monitoring breast cancer or a future target for molecular treatment.

Explore further: New study shows promise for developing new treatments for breast cancer

More information: Breast Cancer Research (in press)

Related Stories

New study shows promise for developing new treatments for breast cancer

March 14, 2012
A new study by University of Kentucky researchers provides insight into developing new treatment strategies for basal-like breast cancer, commonly known as triple-negative breast cancer. This cancer is associated with early ...

Enhancing the effectiveness of a breast cancer treatment

February 13, 2012
Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab (Herceptin) benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. ...

New signaling pathway linked to breast cancer metastasis

April 2, 2012
Lymph nodes help to fight off infections by producing immune cells and filtering foreign materials from the body, such as bacteria or cancer cells. Thus, one of the first places that cancer cells are found when they leave ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.